NRX Pharma Reports 2025 Results, Advances Ketamine Therapy Toward FDA Approval

NRX Pharmaceuticals (NASDAQ: NRXP) reported its full-year 2025 results, highlighting reduced operating expenses, growing revenue, and a cash position of approximately $7.8 million, supporting operations into 2026. The company continues to demonstrate financial discipline while advancing key programs in mental health treatment.

NRX expects potential FDA approval of its preservative-free ketamine therapy in the second half of 2026 and is progressing development of NRX-100, targeting severe depression. The company is also expanding its Hope Therapeutics network, supporting its transition toward commercial growth and revenue generation.

Tags

#NRXPharmaceuticals
#NRXP
#Biotech
#MentalHealth
#KetamineTherapy
#FDAApproval
#DepressionTreatment
#ClinicalTrials
#HealthcareInnovation
#BiotechInvesting
#Neuroplasticity
#Psychiatry
#Pharmaceuticals
#AnaBerry
#NewsOut